← ANALYST RATINGS · TIPRANKS

Azenta (AZTA): analyst forecast and price target

$34.09 −6.65% close 16.10.26 · market cap $1.6B · Healthcare · Medical - Instruments & Supplies IWM 0.05%
Price targets and ratings of

Analyst consensus

Moderate Buy

1 Buy1 Hold0 Sell

Ratings of 2 analysts in the last 3 months · top analysts only

12-month forecast

$34.00−0.3% downside

Based on 2 price targets given in the last 3 months, the average target is $34.00, the highest $35.00, the lowest $33.00. The average is −0.3% from the last price of $34.09.

$20.00$30.00$40.00Jan 26AprJulOctJan 27AprJulOctHigh$35.00Average$34.00Low$33.00
Highest target $35.00 Average target $34.00 Lowest target $33.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
David Saxon★★★★★★★★★★#6662 · hits 38% · avg +0.8% Needham $37.00 Buy +8.5% Reiterated 14.09.26on TipRanks 10:11 +4.3%next day +3.5% · 5 days +3.4%
Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% Evercore ISI $28.00 → $35.00+25.0% Buy +2.7% Reiterated 06.08.26on TipRanks 07:56 −3.2%next day +3.6% · 5 days +9.1%
Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% TD Cowen $20.00 → $33.00+65.0% Hold −3.2% Reiterated 05.08.26on TipRanks 14:50 +5.8%next day −3.2% · 5 days +5.0%
Matthew Stanton, CFA★★★★★★★★★★#10524 · hits 43% · avg −10.9% Jefferies $40.00 → $35.00−12.5% Buy +2.7% Reiterated 01.04.26on TipRanks 14:05 −0.5%next day +6.8% · 5 days +3.2%
Andrew Cooper★★★★★★★★★★#11107 · hits 40% · avg −3.0% Raymond James $35.00 → $45.00+28.6% Buy +32.0% Reiterated 25.11.25on TipRanks 11:40 +2.9%next day −5.5% · 5 days −7.9%
Thomas DeBourcy★★★★★★★★★★#7610 · hits 100% · avg +34.1% Nephron $31.00 Hold −9.1% Upgrade 24.11.25on TipRanks 08:45 +3.7%next day +2.9% · 5 days −6.1%

Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst

Best analysts covering Azenta

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months David Saxon★★★★★★★★★★Needham · #6662
Hits 38%114 of 303 Average return +0.8%
1 year David Saxon★★★★★★★★★★Needham · #6662
Hits 38%114 of 303 Average return +0.8%
2 years David Saxon★★★★★★★★★★Needham · #6662
Hits 38%114 of 303 Average return +0.8%

Most profitable

3 months David Saxon★★★★★★★★★★Needham · #6662
Hits 38%114 of 303 Average return +0.8%
1 year David Saxon★★★★★★★★★★Needham · #6662
Hits 38%114 of 303 Average return +0.8%
2 years David Saxon★★★★★★★★★★Needham · #6662
Hits 38%114 of 303 Average return +0.8%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $35.00 at a price of $34.89 (+0.3%); now: $35.00 at $34.09 (+2.7%).

$30.00$35.00$40.00Sep 15Oct 1Oct 15Top analysts$34.00Average target$35.00Price$34.09

PriceAverage targetTop analysts’ target

Recommendation trend · top analysts

0245Oct 254Nov3Dec12Jan 26112Feb112Mar21Apr11May11Jun1Jul11Aug11Sep11Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy110000
Buy000111
Hold111111
Sell000000

Earnings and sales forecast

Next report: 17.11.26 (Q4 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $0.12 (from $0.05 to $0.15). Last quarter: $0.16.

Sales

Next quarter’s sales estimate — $160M (from $158M to $162M). Last quarter: $161M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Azenta
  • CEO: Martin D. Madaus
  • Employees: 2,900
  • 200 Summit Drive, Burlington, MA, 01803, US
  • www.azenta.com

Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.

Data from the stock’s TipRanks forecast page, read 189 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗